

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Hodge et al.**Application No.** 10/590,844**Filed:** August 24, 2006**Confirmation No.** 8385**For:** SCREENING AGENTS THAT DECREASE
PATHOGENICITY BY DECREASING
RAB11A ACTIVITY**FILED VIA EFS****Examiner:** Sheridan Swope**Art Unit:** 1652**Attorney Reference No.** 6395-68026-07FILED VIA EFS
COMMISSIONER FOR PATENTS**RESPONSE TO RESTRICTION REQUIREMENT**

This document is submitted in response to the Restriction Requirement, dated May 14, 2009, for which a one-month period for reply was set, making a response due on or before June 14, 2009. Applicants request an extension of one month, and pay the requisite fees (\$130.00) herewith via EFS, making a response timely if filed on or before **July 14, 2009**. If additional fees are determined to be required, the Director is hereby authorized to charge any additional fees that may be required, or credit any overpayment, to **Deposit Account No. 02-4550**.

Claims 40, 41, 48, 60 and 61 are pending in this application. The Office alleges that the pending claims are directed to one or more species of the generic invention. The Office has required election to one species of the following retroviruses: human immunodeficiency virus type-1 (HIV-1), human immunodeficiency virus type-2 (HIV-2); equine infectious anemia virus; feline immunodeficiency virus (FIV); feline leukemia viruses (FELV); simian immunodeficiency virus; or avian sarcoma virus.

Applicants hereby elect the retrovirus HIV-1, without traverse. However, as provided by 37 C.F.R. § 1.141, upon allowance of a generic claim, Applicants are entitled to consideration of claims to additional species which are written in independent form or otherwise include all the limitations of an allowed generic claim. All pending claims encompass the elected species.

Substantive examination of the pending claims is respectfully requested. If any minor matters remain to be addressed prior to examination, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

By /Karri Kuenzli Bradley/
Karri Kuenzli Bradley, Ph.D.
Registration No. 56,300